Related Experiment Video
Updated: Sep 8, 2025

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
Prospective Evaluation of Patient Priorities in Human Papillomavirus-Driven Oropharyngeal Cancer Using the Chicago
Lachlan McDowell1, June Corry2, Tsien Fua3
1Department of Radiation Oncology, Princess Alexandra Hospital, Brisbane, Queensland, Australia; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Purpose:
This study examined head and neck cancer treatment outcome priorities in patients with human papillomavirus-associated oropharyngeal cancer (HPVOPC) before and 12 months after (chemo)radiation therapy ([C]RT).
Methods And Materials:
Eligible patients were diagnosed with HPVOPC suitable for curative-intent primary [C]RT. Study data included responses to a modified version of the Chicago Priorities Scale (CPS-modified) and select items from the MDASI Head and Neck Cancer Module. Analysis included descriptive statistics, McNemar's test for binary matched-pairs, and general linear models.
Results:
The CPS-modified was completed by 99 patients before [C]RT, 91 twelve months after [C]RT, and 90 at both assessments. Treatment outcomes classified as top priorities were comparable before and 12 months after [C]RT: "being cured of my cancer" (cure, 93%/91%), "living as long as possible" (survival, 69%/66%), "being able to swallow all foods and drinks" (swallow, 56%/56%), "having a normal amount of energy" (energy, 51%/48%), and "having no pain" (pain, 51%/48%). After [C]RT, cure and survival were ranked highest (1 of 13) by 65 of 90 (72%) and 12 of 90 (13%) patients, respectively, and swallow was ranked above cure, survival, pain, energy, "keeping my normal sense of taste and smell" (senses) and "having a comfortably moist mouth" (moist mouth) by 14%, 36%, 47%, 55%, 56%, and 66% of patients, respectively. More patients identified senses and moist mouth as a top priority 12 months after [C]RT than before [C]RT (26%/44%, P = .002; and 19%/39%, P = .003, respectively). Selected MDASI Head and Neck Cancer Module symptom severity scores did not differ by CPS-modified priority groupings (top vs middle/lower) 12 months after [C]RT (all P > .05).
Conclusions:
For patients with HPVOPC, the most important treatment outcome priorities remained stable before and 12 months after [C]RT. After C[RT], only 56% of HPVOPC survivors considered swallowing a top priority. Patient priorities should be considered when designing future de-escalation treatment strategies, considering the excellent outcomes with standard treatment.
More Related Videos
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
07:43Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples
Published on: July 29, 2017
Related Concept Videos
Cancer Survival Analysis
Treatment Resistant Cancers
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Clinical Trials: Overview
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Clinical Trials
There are four phases in a clinical trial. A phase one...